6 Weight Loss Injections Before and After Cases

What can a before-and-after image tell you about a weight-loss injection, and what does it leave out? A photograph may show a smaller waist, a different facial contour, or a more active posture. It can't show the starting health profile, medication tolerance, nutrition plan, laboratory monitoring, muscle preservation, or whether the result lasted after treatment changed.

This gallery presents six supplied Bel Air-area patient examples organized around different Medical Weight Management challenges. The cases include timelines ranging from five to seven months, weight changes from 26 to 35 pounds, and plans involving GLP-1 receptor agonist injections, nutrition, behavioral support, hormone evaluation, and follow-up. They're examples of individual outcomes, not promises or standardized expectations.

General expectations should be interpreted alongside clinical evidence. In the STEP 1 trial, adults using weekly semaglutide 2.4 mg lost a mean of 14.9% of body weight over 68 weeks, compared with 2.4% with placebo, while 86.4% achieved at least 5% weight loss (STEP 1 trial results). At ProMD Health Bel Air, eligibility, treatment selection, laboratory screening, dosing, side-effect review, nutrition, lifestyle support, and maintenance planning must be determined by the medical team.

Table of Contents

• 1. Patient A and a six-month GLP-1 response
  • What the timeline shows
• 2. Patient B and appetite regulation during midlife
  • The important comparison isn't only before and after
• 3. Patient C after long-term incremental gain
  • Why a longer timeline can be clinically useful
• 4. Patient D and menopause-related abdominal change
  • Read the image with the symptom timeline
• 5. Patient E and the difference between scale and skin
  • Why treatment sequencing protects the final result
• 6. Patient F and metabolic risk beyond appearance
  • The strongest “after” may be functional
• Before & After Comparison: 6 Weight-Loss Injection Cases
• Turn a before-and-after example into a safer next step
  • A practical consultation and safety review

1. Patient A and a six-month GLP-1 response

A 45-year-old woman from Bel Air entered Medical Weight Management after high fasting glucose, metabolic challenges, and repeated difficulty losing weight through diet and exercise alone. Her starting point illustrates why weight loss injections before and after comparisons need more context than a scale or image. Appetite may be part of the problem, but glucose regulation, energy, eating patterns, medication history, and other health factors can shape the plan.

After a metabolic evaluation and consultation with the ProMD Health Bel Air team, she began weekly GLP-1 receptor agonist therapy alongside nutritional counseling and lifestyle changes. Over six months, she lost 32 pounds, reported steadier energy, and described improved confidence. The supplied case notes also associate the outcome with improved insulin sensitivity, but that result belongs to this individual example and shouldn't be presented as a general prediction.

What the timeline shows

Six months is long enough for a treatment plan to include dose adjustments, tolerance checks, nutrition changes, and repeated conversations about habits. It isn't a universal finish line. Clinical trial results develop over longer periods, and a two-year semaglutide study reported mean weight loss of 15.2% at week 104, showing that treatment response can extend beyond the initial trial window (two-year semaglutide data).

The practical lesson is to document more than body weight. Baseline photos, measurements, fasting laboratory results, appetite patterns, energy, and physical activity create a more useful record than a single “before” image.

Practical rule: Keep injection timing consistent, record appetite and energy changes, and ask the care team how nutrition should change as satiety changes.

The supplied plan also describes maintenance injections after the initial treatment period and coordination with existing hormone optimization and aesthetic appointments. Those details require individualized review. A patient shouldn't assume that a maintenance schedule, hormone therapy, Botox, dermal fillers, or any other treatment will be appropriate without medical coordination.

For local patients, the Medical Weight Management service at ProMD Health Bel Air provides the appropriate setting to discuss screening, treatment options, follow-up, and safety. People considering physical activity during treatment can also review exercise while on Wegovy, then confirm any exercise changes with their clinician.

2. Patient B and appetite regulation during midlife

The supplied example of a 52-year-old man from Fallston begins with a familiar frustration. He exercised regularly and had tried diets, yet persistent weight gain continued. His evaluation identified appetite dysregulation, a perceived metabolic slowdown, and declining testosterone levels, creating a case where the visible “after” would need to be interpreted alongside energy, strength, sleep, and activity.

The treatment plan combined weekly weight-loss injection therapy with BioTe testosterone pellet placement. Over five months, he lost 28 pounds and reported a 40% increase in workout capacity, while the case notes describe improved lean muscle retention, appetite stability, and renewed participation in activities. That percentage is specific to this supplied patient example, not a standard outcome for men using injections.

The important comparison isn't only before and after

His initial images showed typical middle-age weight distribution. The later images documented clearer muscle definition and improved posture, but the more meaningful change was behavioral capacity. The plan describes a progression from being unable to run one mile to completing a 5K within three months after treatment began, followed by a return to hiking and cycling that had been abandoned years earlier.

Those details demonstrate why body composition matters. Two people can lose the same amount of weight while experiencing different changes in strength, muscle, waist contour, sleep, or exercise tolerance. A baseline body-composition assessment can therefore add useful context, although the medical team must decide which measurements are appropriate.

A weekly injection can support appetite regulation, but it doesn't replace adequate nutrition or resistance exercise. Patients should discuss protein intake, strength training, hydration, and symptoms such as persistent nausea, constipation, dizziness, or unusual fatigue before changing their routine.

• Measure more than pounds: Track waist measurements, strength, sleep, energy, and exercise tolerance.
• Coordinate therapies: Review hormone treatment and weight-management medication together rather than treating them as separate plans.
• Expect practical changes: Clothing fit and activity tolerance may change before a photograph captures the full difference.

Patients comparing options can review what to expect from physician-supervised weight loss before scheduling a consultation. The central question isn't whether one image looks more dramatic. It's whether the plan is medically appropriate, tolerated, monitored, and compatible with the patient's goals.

3. Patient C after long-term incremental gain

Could a gradual pattern of regain require a longer treatment plan than a short-term weight-loss attempt? A 38-year-old woman from Forest Hill reported weight gain over 15 years after childbirth and career stress. Earlier diets and paid programs produced temporary results followed by regain. Her supplied evaluation identified insulin resistance, subclinical thyroid dysfunction, and leptin dysregulation, so the proposed plan addressed metabolic and behavioral factors alongside medication.

ProMD Health Bel Air designed a program combining GLP-1 receptor agonist injections, thyroid support through specialized supplementation, and behavioral coaching for emotional eating. Over seven months, she lost 35 pounds, established more sustainable eating habits, and reported improved metabolic flexibility. The supplied description of normalized fasting insulin belongs to this case and cannot predict another patient's response.

Why a longer timeline can be clinically useful

The before images represented her highest weight. The after images showed changes in the face, neck, abdomen, and overall contour. The case notes also describe reduced submental fullness, which altered the discussion around possible Kybella treatment, while improved facial definition reduced the immediate need for planned dermal fillers.

Treatment sequencing matters because weight loss can change facial and neck contours before elective aesthetic decisions are finalized. Facial volume, skin laxity, submental fullness, and contour concerns differ among patients. Reassessing those concerns after weight stabilizes may prevent a procedure plan based on an earlier appearance.

The case notes report maintenance of a 32-pound loss 18 months after tapering injections through continued behavioral changes. This is an individual example, not a general expectation. Evidence summarized in Oxford-related reporting on weight regain after stopping medication indicates that regain is common and may occur rapidly after treatment discontinuation, particularly without an effective maintenance strategy. The practical implication is clear: tapering, follow-up, nutrition, activity, and behavioral support require individualized planning with medical supervision.

Weight stabilization is a clinical phase, not merely the moment when the “after” photo is taken.

The supplied process illustration belongs with this case:

Patients with a long history of regain can discuss food patterns, mood, sleep, stress, thyroid history, and prior medications before treatment begins. The gallery comparison is useful when it connects visible change with timeline, measured outcomes, and candidacy. A photograph shows the result, while the treatment record helps explain whether that result is appropriate, tolerated, and maintainable.

4. Patient D and menopause-related abdominal change

How should a before-and-after image be interpreted when menopause, metabolic health, and hormone symptoms overlap?

A 56-year-old postmenopausal woman from Havre de Grace sought care for abdominal weight gain, high cholesterol and glucose, hot flashes, night sweats, and reduced daily quality of life. Her supplied hormone panel showed low estrogen, declining DHEA, and borderline low thyroid function. These findings illustrate why abdominal change during menopause deserves assessment rather than a single-cause assumption. Symptoms, laboratory results, medications, and medical history all affect treatment selection.

The proposed plan combined bioidentical estrogen and DHEA pellets with weekly GLP-1 receptor agonist injections. Over six months, the supplied case records 26 pounds of weight loss and a four-inch reduction in abdominal circumference, along with improved fasting glucose and cholesterol, better posture, and relief from vasomotor symptoms. These are documented details from one patient, not a standard prediction for hormone therapy or injections.

Read the image with the symptom timeline

The before image shows abdominal concentration consistent with the reported presentation. The after image shows a smaller abdomen and improved carriage. The case notes also associate progress with hiking, yoga, and social activities that had become difficult during heavier menopausal years.

The gallery comparison is most useful when the visual change is read beside the timeline and measured outcomes. A patient may value sleep, fewer hot flashes, mobility, mood, posture, and confidence as much as scale weight. Those goals should be identified before therapies are selected or combined.

Patients considering hormone treatment can review Hormone Replacement Therapy at ProMD Health Bel Air and discuss how hormone history, medications, laboratory results, and weight-management goals fit together. Hormone therapy may not suit every patient. GLP-1 treatment also does not replace evaluation of thyroid function, cardiovascular risk, glucose regulation, or other possible causes of symptoms.

• Bring a symptom history: Record hot flashes, night sweats, sleep quality, mood, and activity changes.
• Review laboratory testing: Ask which hormone, metabolic, and thyroid tests inform the consultation.
• Separate association from proof: A visible abdominal change cannot establish that one therapy caused every improvement.
• Plan follow-up: Hormonal effects and metabolic changes may develop on different timelines, so monitoring should reflect both.

The image below is a conceptual illustration, not a photographic patient record.

5. Patient E and the difference between scale and skin

A 48-year-old woman from Abingdon presented with insulin resistance, PCOS-related weight distribution, chronic inflammation, and facial changes associated with prolonged stress and poor metabolic health. The supplied case records a baseline fasting insulin of 18, with a reference range described as below 10, plus high-sensitivity CRP and facial volume loss. Those laboratory values belong to this example and aren't a universal starting profile.

The integrated plan used GLP-1 receptor agonist injections, anti-inflammatory supplementation through The Skin Shoppe, stress-management support, and delayed aesthetic maintenance. Over six months, she lost 29 pounds, reached a fasting insulin of 8, and reported better skin texture and facial fullness. The supplied notes also report a 40% reduction in inflammatory markers, including CRP changing from 4.2 to 2.5.

Why treatment sequencing protects the final result

The patient expected to consider dermal fillers and microneedling, but the plan delayed those decisions until metabolic changes had settled. That approach recognizes that weight reduction can alter facial fullness and contour. A filler plan chosen before stabilization may not reflect the patient's later needs.

The visible before-and-after difference included a less puffy facial appearance, clearer contour, and improved skin quality. Those changes are described in the supplied case, but readers shouldn't infer that injections alone improve skin texture or eliminate the need for every aesthetic procedure. Nutrition, sleep, stress, skincare, supplements, genetics, sun exposure, and other factors can influence appearance.

A real-world semaglutide study in adults without diabetes reported a median six-month loss of 13.3%, or 14.9 kilograms, and 68% of 25 participants reached at least 10% weight loss (real-world semaglutide study). That evidence helps frame why individual results vary. A supplied patient example with a pound-based outcome and a study expressed as percentage weight change aren't interchangeable.

Clinical perspective: If the face is changing during weight loss, reassess elective volume treatment after the medical plan has had time to work.

Patients may ask whether inflammatory markers, insulin measures, skincare, supplements, or aesthetic treatments belong in the same conversation. The answer depends on the medical history and goals. ProMD Health Bel Air can review those questions within the scope of its Medical Weight Management and approved skincare and supplement services.

6. Patient F and metabolic risk beyond appearance

A 41-year-old man from Forest Hill had gained more than 40 pounds over five years while coping with career stress, poor sleep, and reduced activity. His supplied workup described abdominal obesity, triglycerides of 340, fasting glucose of 108, borderline high blood pressure, inflammatory markers, low testosterone, and cortisol. This is a more complex starting point than a cosmetic weight-loss goal.

The proposed plan combined GLP-1 receptor agonist injections, testosterone optimization with BioTe pellets, stress-reduction coaching, and sleep-hygiene support. Over six months, he lost 31 pounds. The supplied case also reports triglycerides of 180, fasting glucose of 95, reduced blood pressure, renewed athletic activity, and improved work and family engagement.

The strongest “after” may be functional

The before image showed abdominal obesity and poor posture. The after image showed a smaller abdomen, more visible muscle definition, and improved carriage. The patient also progressed from a sedentary routine to completing a 10K race five months after treatment began, according to the supplied example.

Those outcomes should be separated carefully. Weight loss may coincide with improved laboratory results and activity, but a photograph can't establish cardiovascular risk or confirm that a particular marker normalized. The medical team must interpret repeated laboratory values, blood pressure readings, medication changes, symptoms, exercise tolerance, and nutrition together.

A large real-world cohort reported one-year mean weight loss of 14.1% with semaglutide 2.4 mg and 16.5% with tirzepatide, corresponding to 14.6 kilograms and 17.2 kilograms, respectively (one-year real-world comparison). The figures offer a population-level benchmark, while Patient F's pound-based result remains an individual case. Neither tells a new patient exactly what will happen.

• Screen the full picture: Review glucose, lipids, blood pressure, sleep, stress, hormones, medications, and activity.
• Protect function: Pair weight loss with clinician-approved resistance and aerobic activity.
• Monitor trends: One improved reading is less informative than a pattern reviewed by the care team.
• Plan for maintenance: Discuss what happens if weight loss slows, treatment changes, or side effects limit dosing.

The image below illustrates the concept of a metabolic transformation rather than documenting a verified patient photograph.

Before & After Comparison: 6 Weight-Loss Injection Cases

Turn a before-and-after example into a safer next step

The six examples point to a consistent conclusion: weight loss injections before and after results depend on the starting condition, treatment choice, tolerance, nutrition, activity, follow-up, and time. A person with insulin resistance may need a different evaluation from someone whose primary concerns involve menopause, sleep, stress, or appetite. Even two people using the same medication can have different responses.

Clinical evidence supports meaningful average results, but averages don't define an individual. In the SURMOUNT-1 trial, tirzepatide produced mean weight changes of 15.0% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg over 72 weeks, compared with 3.1% with placebo (SURMOUNT-1 results). In a head-to-head study, tirzepatide produced 20.2% average weight loss over 72 weeks, compared with 13.7% for semaglutide, a relative advantage of 47% (head-to-head trial report). These are trial findings, not guarantees.

Photographs become more useful when taken under comparable lighting, posture, clothing, camera distance, and timing. They should be reviewed with weight, waist measurements, body-composition information when appropriate, laboratory results, appetite, energy, strength, medication tolerance, and quality-of-life changes.

A practical consultation and safety review

Before starting, bring a complete medication and supplement list, relevant medical history, prior weight-loss attempts, pregnancy or breastfeeding considerations, endocrine history, gastrointestinal history, and personal goals. The medical team should determine eligibility and review whether a prescription injection is appropriate.

Discuss these points during care:

• Baseline information: Record weight, measurements, photographs, relevant laboratory work, blood pressure, symptoms, and current activity.
• Treatment selection: Ask why a particular medication and dose are being considered, and how titration will be supervised.
• Side effects: Review expected symptoms, warning signs, hydration, nutrition, and when to contact the clinic.
• Muscle and nutrition: Discuss adequate food quality, protein, resistance training, and strategies to avoid becoming smaller but weaker.
• Medication coordination: Review hormone therapy, diabetes medications, supplements, anesthesia plans, and other prescriptions.
• Follow-up: Confirm how often progress, laboratory results, appetite, energy, and adverse effects will be assessed.
• Maintenance: Ask how long treatment may continue, what could happen after discontinuation, and what plan would address regain.

Stopping treatment deserves its own conversation. An Oxford review summarized by recent reporting on post-treatment regain describes weight increasing by about 0.4 kilograms per month after weight-management drugs were stopped, with an estimated return to starting weight within 1.5 to 2 years. A separate meta-analysis reported pooled regain of 9.69 kilograms for semaglutide and tirzepatide and 2.20 kilograms for liraglutide after discontinuation (discontinuation meta-analysis). Those findings make maintenance planning part of treatment, not an optional discussion after the final photograph.

For adults in Bel Air, Fallston, Forest Hill, Abingdon, Havre de Grace, and surrounding areas, ProMD Health Bel Air offers medically supervised Medical Weight Management with consultation, screening, follow-up, and individualized treatment planning. Request a virtual or in-person consultation to discuss whether weight-loss injections fit your medical history, goals, and long-term maintenance needs.

ProMD Health Bel Air provides Medical Weight Management and weight-loss injection consultations for adults seeking a medically supervised plan, with screening and follow-up built into care. Visit ProMD Health Bel Air to request a virtual or in-person consultation in Bel Air and discuss your safest next step.